Bayer Adjusts 2025 Sales Forecast and Increases US Litigation Provisions

Key highlights
  • Bayer expects 2025 Group sales of €46-48B and EBITDA of €9.7-10.2B.
  • Q2 2025 sales reached €10.7B, with Crop Science sales up 2.2%.
  • Bayer allocated €1.2B for Roundup litigation, settling 131,000 claims.
  • Bayer anticipates special items in EBITDA to be -€3.5 to -€2.5B for 2025.

Financial Update

Bayer has revised its 2025 financial guidance, projecting Group sales of €46 to €48 billion and EBITDA before special items of €9.7 to €10.2 billion. The company expects core earnings per share to be between €4.80 and €5.30. Currency effects are anticipated to reduce Group sales by €2 billion and EBITDA by €500 million, while positively impacting net financial debt by €1.2 billion.

Q2 2025 Performance

In the second quarter of 2025, Bayer reported Group sales of approximately €10.7 billion. Crop Science sales increased by 2.2% on a currency- and portfolio-adjusted basis, while Pharmaceuticals and Consumer Health divisions saw marginal sales growth. Group EBITDA before special items was around €2.1 billion, with divisional EBITDA at €0.7 billion for Crop Science, €1.1 billion for Pharmaceuticals, and €0.3 billion for Consumer Health.

Litigation and Provisions

Bayer has set aside €1.2 billion for Roundup litigation, part of a total €1.7 billion provision for US legal issues. The company has settled 131,000 of 192,000 glyphosate claims, reducing unresolved claims to 61,000. Additional provisions of €530 million were recorded for PCB-related cases, including the Burke case and potential settlements related to the Sky Valley Education Center.

Special Items and Future Outlook

Special items in EBIT for Q2 totaled approximately -€1 billion, mainly due to impairment loss reversals and litigation provisions. For the full year, Bayer expects special items in EBITDA to range from -€3.5 to -€2.5 billion. The company continues to monitor geopolitical developments and their financial impacts.

Source: Bayer

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

30 October 2026
Monsanto wins unanimous defense verdict in first post‑Durnell Roundup trial

Jury cleared Monsanto on design‑defect, fraud and negligence claims in a three‑plaintiff case — the first Roundup trial after the Supreme Court’s June 2026 Durnell ruling.

30 July 2025
Bayer Seeks Herbicide Approval in Four Key Markets

Icafolin-methyl, a new herbicide, targets weed resistance with unique properties. Launch expected in Brazil by 2028, with further expansion planned.